DEF: T Stamp Reschedules Annual Meeting, Seeks Warrant Approval

T Stamp Inc. has rescheduled its 2025 Annual Meeting of Stockholders to March 11, 2026, to vote on director elections, auditor ratification, and the crucial approval of private placement warrants.

Summary

• The 2025 Annual Meeting of Stockholders has been deferred and rescheduled to Wednesday, March 11, 2026, at 9:00 a.m. Eastern Standard Time, and will be held entirely online via audio webcast.
• The record date for stockholders entitled to vote at the Deferred Annual Meeting is January 15, 2026.
• Stockholders will vote on three key proposals: (1) the election of two Class III directors to serve until the 2028 Annual Meeting, (2) the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and (3) the ratification and approval of the issuance of Private Placement Warrants and the shares issuable upon their exercise, as required by Nasdaq Listing Rule 5635(d).
• The Private Placement Warrants, issued pursuant to a Securities Purchase Agreement (Armistice SPA) dated December 5, 2024, with Armistice Capital Master Fund Ltd., are exercisable for up to 648,148 shares of Class A Common Stock at an exercise price of $8.10 per share.
• The company previously failed to obtain a sufficient number of votes to constitute a quorum for shareholder approval of the Armistice SPA at meetings held on February 7, 2025, May 15, 2025, and December 30, 2025.
• The December 2024 offering, which included a registered direct offering and the private placement, raised approximately $3.0 million in gross proceeds.
• If all Private Placement Warrants are exercised for cash, the company expects to receive an additional approximately $5,249,993 in gross proceeds.
• Audit fees billed by CBIZ CPAs P.C. for the fiscal year ended December 31, 2024, were $473,665.
• Total compensation for the Chief Executive Officer, Gareth Genner, was $682,500 for 2025, consisting of salary and stock awards.
• Total compensation for the President, Andrew Gowasack, was $552,286 for 2025, consisting of salary and stock awards.
• Total compensation for the Chief Technology Officer, Andrew Scott Francis, was $410,792 for 2025, consisting of salary and stock awards.
• Directors as a group received $240,000 for their services in 2025.
• As of January 22, 2026, 28.57% of the company's directors were female, and the Board is committed to including diversity as a factor in director nominations.

Sentiment

Score: 4

Explanation: While the company secured a capital raise, the repeated failures to obtain shareholder approval for the warrants, the explicit risks of dilution, and the potential loss of significant future proceeds if not approved, indicate underlying operational or governance challenges that temper any positive sentiment from the capital raise itself. The need for this amendment highlights ongoing issues.

Positives

• The company successfully completed a registered direct offering and concurrent private placement in December 2024, raising approximately $3.0 million in gross proceeds.
• There is a potential for an additional $5,249,993 in gross proceeds if the Private Placement Warrants are fully exercised, which would support working capital and general corporate purposes.
• The Board of Directors recommends voting FOR all proposals, including the ratification of the Private Placement Warrants, indicating management's belief in their strategic importance.
• The Board is committed to maintaining and growing a diverse and broad skill set, with 28.57% female directors as of January 22, 2026, and a stated commitment to increasing gender, racial, ethnic, sexual orientation, and/or cultural diversity.

Negatives

• The company has repeatedly failed to obtain a sufficient number of votes to constitute a quorum for shareholder approval of the Armistice SPA and related warrant issuance at three prior meetings (February 7, 2025, May 15, 2025, and December 30, 2025).
• Failure to approve Proposal 3 (ratification of Private Placement Warrants) will prevent the company from receiving approximately $5.25 million in gross proceeds from their exercise, which could adversely impact its ability to fund operations.
• If Proposal 3 is not approved, the company will incur substantial additional costs and expenses by needing to hold another meeting every ninety days thereafter to seek Shareholder Approval.
• Approval of Proposal 3 will result in dilution for existing stockholders upon the issuance of up to 648,148 shares of Class A Common Stock from the exercise of the Private Placement Warrants.
• The sale of these additional shares into the public market could materially and adversely affect the market price of the Class A Common Stock.

Risks

• Inability to fund operations if Private Placement Warrants cannot be exercised, foregoing approximately $5.25 million in gross proceeds.
• Dilution of existing stockholder ownership interests upon the issuance of shares from warrant exercise.
• Potential adverse effect on the market price of Class A Common Stock due to the sale of shares from warrant exercise into the public market.
• Incurrence of substantial additional costs and expenses if Proposal 3 is not approved, requiring further meetings every 90 days.

Future Outlook

The company's primary use of the net proceeds from the Armistice SPA is for working capital, capital expenditures, and other general corporate purposes. The company is required to file a registration statement for the resale of shares of Class A Common Stock issued and issuable upon the exercise of the Private Placement Warrants within 30 days of December 5, 2024, and use commercially reasonable efforts to cause it to become effective within 91 days. If shareholder approval for the Private Placement Warrants is not obtained at the Deferred Annual Meeting, the company must call a meeting every ninety days thereafter to seek approval until it is obtained or the warrants are no longer outstanding.

Management Comments

• "We cordially invite you to attend the deferred 2025 Annual Meeting of Stockholders of T Stamp Inc. dba Trust Stamp." Gareth Genner, Chief Executive Officer.
• "Your vote is important. We encourage you to review the proxy materials and vote as soon as possible." Gareth Genner, Chief Executive Officer.
• The Board has no reason to believe that any of the persons named as a nominee for the Board will be unable, or will decline, to serve as a member of the Board if elected.
• The Board believes that the latest directors have provided valuable experience and insight and that it is important to have a diverse Board.

Industry Context

This filing primarily addresses company-specific corporate governance matters and the ratification of a past capital raise, rather than broader industry trends or competitive positioning. The need for shareholder approval under Nasdaq listing rules is a standard regulatory requirement for certain transactions.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not aware of any of its directors currently being subject to any litigation, nor is it aware of any pending or threatened legal actions against its directors.

Related Party Transactions

• QID Technologies LLC: The company owns a 10% equity interest in QID Technologies LLC, a subsidiary formed with Qenta. The company provides technical services to QID via a Master Technology Service Agreement (effective January 1, 2025) with an initial minimum payment of $100,000 per calendar month. Qenta and DQI Holdings Inc. (which has an ownership interest in Trust Stamp) have a common owner, establishing a related party relationship.
• Mutual Channel Agreement with Vital4Data, Inc.: The company has an agreement with Vital4Data, Inc., where one of its directors serves as CEO. The company engaged Vital4Data as a non-exclusive sales representative, with commissions ranging from 20% to 5% of net revenue over three years. No commissions have been earned or expensed to date.
• Channel Partnership Agreement with CyberFish: The company has an agreement with CyberFish, where director Berta Pappenheim serves as CEO. Trust Stamp sells CyberFish services and is entitled to a 30% commission on net revenue. No commissions have been earned to date.

Stakeholder Impact

• Shareholders: Will participate in voting on critical corporate governance matters and a significant capital raise ratification. Face potential dilution if warrants are approved and exercised, and could experience impacts on stock price.
• Armistice Capital Master Fund Ltd.: The investor in the private placement is awaiting shareholder approval for the Private Placement Warrants to become fully exercisable, which is crucial for their investment realization.
• Management and Board of Directors: Are responsible for securing shareholder approval for the warrants, managing the company's operations, and addressing the challenges of obtaining quorum for shareholder meetings.
• Employees: The capital raised and potential future proceeds are intended for working capital and general corporate purposes, which could support ongoing operations and stability.

Next Steps

• Stockholders are encouraged to review proxy materials and vote on the election of Class III directors, ratification of the independent auditor, and ratification of the Private Placement Warrants at the Deferred Annual Meeting on March 11, 2026.
• The company will announce preliminary voting results at the Deferred Annual Meeting and publish final results in a Current Report on Form 8-K within four business days following the meeting.
• If Proposal 3 is not approved, the company must call a meeting every 90 days thereafter to seek Shareholder Approval until it is obtained or the warrants are no longer outstanding.
• The company is required to file a registration statement for the resale of shares from Private Placement Warrants within 30 days of December 5, 2024, and use commercially reasonable efforts to cause it to become effective within 91 days.

Key Dates

Recommendation

The company is in a critical phase of securing shareholder approval for private placement warrants that could bring in over $5 million in additional capital, which is positive for liquidity and operations. However, the repeated failures to secure a quorum for this approval in prior meetings raise concerns about corporate governance and shareholder engagement. Furthermore, the approval and subsequent exercise of these warrants will result in significant dilution for existing shareholders, which could negatively impact the stock price. Investors should monitor the outcome of the March 11, 2026 meeting and the company's ability to effectively utilize the capital while managing the dilutive effects before making a more definitive investment decision.

Keywords

T Stamp, Trust Stamp, SEC filing, DEF 14A, proxy statement, annual meeting, stockholder vote, corporate governance, director election, auditor ratification, private placement warrants, Armistice Capital, Nasdaq listing rules, capital raise, dilution, financial reporting, CBIZ CPAs